印度尼西亚开始M72结核病疫苗临床试验, Indonesia starts clinical trials for the M72 TB vaccine, aiming to combat high TB rates.

印度尼西亚已开始对M72肺结核疫苗进行第3阶段临床试验,鉴于该国结核病发病率高,这是一项重要的保健倡议。 Indonesia has begun phase 3 clinical trials for the M72 tuberculosis vaccine, a significant health initiative given the country's high TB rates. 这次试验得到比尔及梅林达·盖茨基金会的支持,有2 000人参加,目的是评估疫苗的有效性和安全性。 The trial, supported by the Bill & Melinda Gates Foundation, involves 2,000 participants and aims to assess the vaccine's effectiveness and safety. 卫生官员澄清说,试验不是试验性的,是全球研究的一部分,有20 000人参加。 Health officials clarify that the trial is not experimental and is part of a global study with 20,000 participants. 如果取得成功,可导致国内疫苗生产和改进结核病管理战略。 If successful, it could lead to domestic vaccine production and improved TB management strategies.